Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
Tamir brings more than 20 years of experience in the medical technology sector
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
Health innovations are viewed more positively than food and agricultural technologies
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Subscribe To Our Newsletter & Stay Updated
